Deleted Tweets From Scott Gottlieb, R-D.C.

STAT: “The FDA has taken a big step in encouraging drug companies to include pregnant women in clinical trials, issuing a draft guidance outlining how to do so safely and ethically.” https://t.co/oQYIp55C5J

Consumers who have symptoms of E. coli O157:H7 infection should contact their health care provider to report their symptoms and receive care.

#FDA along with @CDCgov and state and local partners, are investigating a multistate outbreak of E. coli O157:H7 illnesses that have sickened 17 people in 7 states: https://t.co/NbHRoOELrd

#FDA is working with its partners to determine what people ate before they became ill, but no specific food item has been identified as a likely source of the infections at this time.

Artificial Intelligence (AI) and Machine Learning (ML) hold enormous promise for the future of medicine. FDA is taking steps to promote innovation and support the use of artificial intelligence based medical devices

Our approach will continue to leverage real world evidence and incorporate safeguards for safety and quality. We’re working with sponsors and researchers on the cutting edge of AI/ML to make sure our regulatory approach supports the development of safe an

We’re moving toward using pre-cert approach for AI software that needs to continue to learn and improve as it’s used. We’re developing an efficient regulatory approach for review of AI algorithms used to diagnose and treat disease.

We’re working with providers and consumers to address technology & safety questions re: continuous learning AI. Our approach will establish appropriate guardrails to allow advances in machine learning, ensure devices can rapidly make improvements with

RT @_bakulpatel: #DigitalHealth https://t.co/3tHduwnxtL QT @SGottliebFDA: We’re moving toward using pre-cert approach for AI software that needs to continue to learn and improve as it’s use… https://t.co/uEMxfC6Y22)

RT @SGottliebFDA: Artificial Intelligence (AI) and Machine Learning (ML) hold enormous promise for the future of medicine. FDA is tak… https://t.co/yGZR72rlFb

RT @dgingery: This is interesting... https://t.co/6y7sv38auK QT @SGottliebFDA: We’re moving toward using pre-cert approach for AI software that needs to continue to learn and improve as it’s use… https://t.co/uEMxfC6Y22)

#FDA working diligently to ensure that our regulations are as nimble and sophisticated as the science driving Next Generation Sequencing technologies with release of two new guidances today on NGS development: https://t.co/QAz7Bepj82 https://t.co/4l22BAnR

One of the guidances released today by @US_FDA discusses analytical validation of NGS-based tests to help diagnose suspected germline diseases. Guidance recs could spur the creation of consensus standards for NGS-based tests developed by the community: ht

Another #FDA guidance finalized today describes considerations for recognizing publicly accessible genetic variant databases as sources of valid scientific evidence to support clinical validity during premarket review: https://t.co/QAz7Bepj82

RT @steveusdin1: .@SGottliebFDA presents new cancer diagnostic guidance documents as part of broader policies to reduce cost and im… https://t.co/t3nfFC1JlR

RT @FishburnSimone: FDA continuing the push for innovation in NGS technologies for cancer diagnostics, under @SGottliebFDA, with 3 new guid… QT @steveusdin1: FDA streamlining cancer diagnostics development @SGottliebFDA announces. This will advance precision medicine. https://t.co/vAiMRFPPqO)

RT @dgingery: New guidance... https://t.co/3JWIhqnPk1 QT @FDAMedia: FDA advances policy to make co-development of drugs and diagnostics in cancer trials more efficient: https://t.co/KLW2pQ9RfE)

RT @FDAMedia: FDA advances policy to make co-development of drugs and diagnostics in cancer trials more efficient: https://t.co/KLW2pQ9RfE

RT @tmprowell: Just out: 2 important new @US_FDA guidances to accelerate development NGS-based tests, including one on use of public human… QT @FDAMedia: FDA finalizes guidances to accelerate the development of reliable, beneficial next generation sequencing-based test… https://t.co/j9eTJ1i28a)

RT @steveusdin1: AI diagnostic software gets FDA approval for diabetic retinopathy. Very cool. Much more like this to come. FDA is c… https://t.co/zZwmxlrbko

STAT: “The FDA has taken a big step in encouraging drug companies to include pregnant women in clinical trials, issuing a draft guidance outlining how to do so safely and ethically.” https://t.co/oQYIp55C5J

Consumers who have symptoms of E. coli O157:H7 infection should contact their health care provider to report their symptoms and receive care.

#FDA along with @CDCgov and state and local partners, are investigating a multistate outbreak of E. coli O157:H7 illnesses that have sickened 17 people in 7 states: https://t.co/NbHRoOELrd

#FDA is working with its partners to determine what people ate before they became ill, but no specific food item has been identified as a likely source of the infections at this time.

Artificial Intelligence (AI) and Machine Learning (ML) hold enormous promise for the future of medicine. FDA is taking steps to promote innovation and support the use of artificial intelligence based medical devices

Our approach will continue to leverage real world evidence and incorporate safeguards for safety and quality. We’re working with sponsors and researchers on the cutting edge of AI/ML to make sure our regulatory approach supports the development of safe an

We’re moving toward using pre-cert approach for AI software that needs to continue to learn and improve as it’s used. We’re developing an efficient regulatory approach for review of AI algorithms used to diagnose and treat disease.

We’re working with providers and consumers to address technology & safety questions re: continuous learning AI. Our approach will establish appropriate guardrails to allow advances in machine learning, ensure devices can rapidly make improvements with

RT @_bakulpatel: #DigitalHealth https://t.co/3tHduwnxtL QT @SGottliebFDA: We’re moving toward using pre-cert approach for AI software that needs to continue to learn and improve as it’s use… https://t.co/uEMxfC6Y22)

RT @SGottliebFDA: Artificial Intelligence (AI) and Machine Learning (ML) hold enormous promise for the future of medicine. FDA is tak… https://t.co/yGZR72rlFb

RT @dgingery: This is interesting... https://t.co/6y7sv38auK QT @SGottliebFDA: We’re moving toward using pre-cert approach for AI software that needs to continue to learn and improve as it’s use… https://t.co/uEMxfC6Y22)

#FDA working diligently to ensure that our regulations are as nimble and sophisticated as the science driving Next Generation Sequencing technologies with release of two new guidances today on NGS development: https://t.co/QAz7Bepj82 https://t.co/4l22BAnR

One of the guidances released today by @US_FDA discusses analytical validation of NGS-based tests to help diagnose suspected germline diseases. Guidance recs could spur the creation of consensus standards for NGS-based tests developed by the community: ht

Another #FDA guidance finalized today describes considerations for recognizing publicly accessible genetic variant databases as sources of valid scientific evidence to support clinical validity during premarket review: https://t.co/QAz7Bepj82

RT @steveusdin1: .@SGottliebFDA presents new cancer diagnostic guidance documents as part of broader policies to reduce cost and im… https://t.co/t3nfFC1JlR

RT @FishburnSimone: FDA continuing the push for innovation in NGS technologies for cancer diagnostics, under @SGottliebFDA, with 3 new guid… QT @steveusdin1: FDA streamlining cancer diagnostics development @SGottliebFDA announces. This will advance precision medicine. https://t.co/vAiMRFPPqO)

RT @dgingery: New guidance... https://t.co/3JWIhqnPk1 QT @FDAMedia: FDA advances policy to make co-development of drugs and diagnostics in cancer trials more efficient: https://t.co/KLW2pQ9RfE)

RT @FDAMedia: FDA advances policy to make co-development of drugs and diagnostics in cancer trials more efficient: https://t.co/KLW2pQ9RfE

RT @tmprowell: Just out: 2 important new @US_FDA guidances to accelerate development NGS-based tests, including one on use of public human… QT @FDAMedia: FDA finalizes guidances to accelerate the development of reliable, beneficial next generation sequencing-based test… https://t.co/j9eTJ1i28a)

RT @steveusdin1: AI diagnostic software gets FDA approval for diabetic retinopathy. Very cool. Much more like this to come. FDA is c… https://t.co/zZwmxlrbko